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Infrequent methylation of CDKN2A(MTS1p16) and rare
mutation of both CDKN2A and CDKN2B(MTS2Ip15) in
primary astrocytic tumours
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Institute for Oncology and Pathology, Division of Tumour Pathology, and Ludwig Institute for Cancer Research, Stockholm Branch, Karolinska Hospital,
S-171 76 Stockholm, Sweden
Summary In a series of 46 glioblastomas, 16 anaplastic astrocytomas and eight astrocytomas, all tumours retaining one or both alleles of
CDKN2A (48 tumours) and CDKN2B (49 tumours) were subjected to sequence analysis (entire coding region and splice acceptor and donor
sites). One glioblastoma with hemizygous deletion of CDKN2A showed a missense mutation in exon 2 (codon 83) that would result in the
substitution of tyrosine for histidine in the protein. None of the tumours retaining alleles of CDKN2B showed mutations of this gene.
Glioblastomas with retention of both alleles of CDKN2A (14 tumours) and CDKN2B (16 tumours) expressed transcripts for these genes. In
contrast, 7/13 glioblastomas with hemizygous deletions of CDKN2A and 8/11 glioblastomas with hemizygous deletions of CDKN2B showed
no or weak expression. Anaplastic astrocytomas and astrocytomas showed a considerable variation in the expression of both genes,
regardless of whether they retained one or two copies of the genes. The methylation status of the 5' CpG island of the CDKN2A gene
was studied in all 15 tumours retaining only one allele of CDKN2A as well as in the six tumours showing no significant expression of
transcript despite their retaining both CDKN2A alleles. Three tumours (one of each malignancy grade studied) were found to have partially
methylated the 5' CpG island of CDKN2A. It appears that in human astrocytic gliomas point mutations of the CDKN2A and CDKN2B genes
are uncommon and hypermethylation of the 5' CpG region of CDKN2A does not appear to be a major mechanism for inhibiting transcription
of this gene.
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The CDKN2A/MTSJ/pJ6'NK4A and CDKN2B/MTS2/pJ5INK4B cyclin-
dependent kinase inhibitor genes were mapped to 9p2l (Kamb et
al, 1994a; Nobori et al, 1994) and found to be deleted in many
types of human neoplasms. The gene products, p16 and p15, bind
to Cdk4, thereby preventing the formation of the Cdk4/cyclinD
complexes required for the phosphorylation of the Rbl protein, a
prerequisite for progression of normal cells from G, into the S-
phase of the cell cycle (Serrano et al, 1993; Hannon and Beach,
1994). Loss ofCDKN2A and CDKN2B expression should promote
Cdk4/cyclinDl complex formation. We have previously shown
homozygous deletions ofthese genes in 19/46 glioblastomas, 3/16
anaplastic astrocytomas and in 0/8 astrocytomas (Schmidt et al,
1994). In addition, CDK4 gene amplification with overexpression
was found in approximately 15% of these tumours (Reifenberger
et al, 1994) and was seen almost exclusively in tumours without
deletions of CDKN2A and CDKN2B. Thus, two different aberra-
tions of the same pathway may lead to increased Cdk4/cyclinDl
formation in astrocytic gliomas (Schmidt et al, 1994).
Point mutations in CDKN2A have been shown in tumours
retaining one allele, and in some cases have been shown to result in
a protein unable to bind Cdk4. Tumours with such mutations of
CDKN2A include pancreatic adenocarcinomas (Caldas et al, 1994),
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oesophageal squamous cell carcinomas (Mori et al, 1994), familial
melanomas (Hussussian et al, 1994; Kamb et al, 1994b), non-
small-cell lung carcinomas (NSCLC) (Washimi et al, 1995) and
single cases of gliomas (Ueki et al, 1994, 1996; Li et al, 1995;
Moulton et al, 1995). Hypermethylation ofthe 5' CpG island ofthe
CDKN2A gene has been reported as a mechanism inhibiting gene
expression in some tumour cells (Gonzalez-Zulueta et al, 1995;
Herman et al, 1995; Merlo et al, 1995; Otterson et al, 1995). The
CDKN2B gene has not been examined to the same extent.
In order to obtain further evidence that loss of a functional p16
and p15 protein is involved in the progression of astrocytic
tumours, we studied our tumour series forpoint mutations ofthese
genes. The transcript expression of these genes was also exam-
ined, and in the case of CDKN2A it was correlated with a study of
the methylation ofthe CpG island in the 5' region ofthis gene. The
findings show that mutations are infrequent and methylation does
not appear to be a major mechanism inhibiting CDKN2A transcrip-
tion in primary astrocytic tumours.
MATERIALS AND METHODS
Tumour and control tissue, DNA and RNA extraction
The material consisted of 70 tumours including 46 glioblastomas
(GB), 16 anaplastic astrocytomas (AA) and eight astrocytomas
(A). All have been reported previously using the same tumour
numbers (Schmidt et al, 1994). DNA and RNA were extracted
as described previously (Reifenberger et al, 1993). In addition,
non-neoplastic adult human brain tissue (cortex and white matter)
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Table 1 Primer sequences for template preparation, cycle sequencing, RT-PCR and methylation analysis
Genes/exons PCR primers Ta(°C) Sequencing primers
Sequencing
CDKN2A
Exon 1 Forward 2FUb CCCAGTCACGACGTTGTAAAACGACG- 58 M13-21 GTAAAACGACGGCCAGT
GCCAGTGAAGAAAGAGGAGGGGCTG PC778 CGGAGAGGGGGAGAGCAGG
Reverse 1108Rb GCGCTACCTGATTCCAATTC 1108Rb GCGCTACCTGATTCCAATTC
Exon 2 Forward 42Fb GGAAATTGGAAACTGGAAGC 58 PC742 AGCTTCCTTTCCGTCATGCC
Reverse 551 RUb CCCAGTCACGACGTTGTAAAACGACG- 551 Rb TCTGAGCTTTGGAAGCTCT
GCCATTCTGAGCTTTGGAAGCTCT
Exon 3 Forward X3.90Fc CCGGTAGGGACGGCAAGAGA 60
Reverse 530Rc CTGTAGGACCCTCGGTGACTGATGA 530Rc CTGTAGGACCCTCGGTGACTGATGA
CDKN2B
Exon 1 Forward p15E1.51d AAGAGTGTCGTTAAGTTTACG 55 P15E1.51d AAGAGTGTCGTTAAGTTTACG
Reverse p15E1.32d ACATCGGCGATCTAGGTTCCA p15E1.32d ACATCGGCGATCTAGGTTCCA
Exon 2 Forward 89Fb TGAGTTTAACCTGAAGGTGG 58 89Fb TGAGTTTAACCTGAAGGTGG
Reverse 5ORb GGGTGGGAAATTGGGTAAG 5ORb GGGTGGGAAATTGGGTAAG
RT-PCR
CDKN2A Forward PC703 CAACGCACCGAATAGTTACGGTC 59
Reverse PC704 TCTATGCGGGCATGGTTACTG
CDKN2B Forward PC738 AGGACGACGGGAGGGTAATG 55
Reverse PC739 GCCTTCATCGAATTAGGTGGGTG
f3-Actin Forward PC359 GGCATCGTGATGGACTCCG 55
Reverse PC360 GCTGGAAGGTGGACAGCGA
Methylation analysis
CDKN2A
Exon 1 Forward 2Fb GAAGAAAGAGGAGGGGCTG 58
Reverse 1108Rb GCGCTACCTGATTCCAATTC
aAnnealing temperatures. bKamb et al (1994a). cHussussian et al (1994). dPrimer sequences kindly provided by Dr David Beach.
from the temporal lobe of a patient operated on for epilepsy and
total brain RNA (purchased from Clontech, Palo Alto, CA, USA)
was used.
Template preparation and sequencing
Sequencing templates were prepared by polymerase chain reaction
(PCR) amplification of genomic DNA fragments using primers
flanking the coding regions (see Table 1). Genomic DNA (100 ng)
served as template in 50-gl reactions and was amplified in 30
cycles. PCR products were purified by the Wizard PCR kit
(Promega, Madison, WI, USA). Aliquots of 1-8 tl of PCR
product were used as templates for cycle sequencing. The Prism
Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA, USA) was used according
to the manufacturer's instructions. The samples were run on a 373
DNA Sequencer (Applied Biosystems, Foster City, CA, USA) and
the sequences were analysed using the Sequence Navigator soft-
ware (Applied Biosystems). To compensate for uneven peaks
due to Taq polymerase differential nucleotide preference,
sequencing was performed on both DNA strands. A minimum of
ten nucleotides of the adjacent intron sequences were included in
the analysis.
Reverse transcriptase-polymerase chain reaction
(RT-PCR)
The primers used for amplification of CDKN2A and CDKN2B
cDNA are listed in Table 1. For both genes, the forward and
reverse primers were selected from different exons in order to
ensure that amplification of contaminating genomic DNA would
result in a PCR product of different size. r-Actin cDNA was
amplified for assessment of cDNA quantity. PCR reactions were
performed for 30 cycles, loaded onto a 1% agarose gel, and
ethidium bromide-stained bands were visualized and recorded by
the Eagle Eye II system (Stratagene, La Jolla, CA, USA).
Southern blotting analysis
DNA (4 ,ug) was digested with SmaI and EcoRL, electrophoresed
and blotted onto nylon membranes. Blots were then hybridized
with a CDKN2A exon 1 probe (Schmidt et al, 1994), exposed
on Storage Phosphor Screens and analysed using a Phosphor-
Imager as previously described (Schmidt et al, 1994). This probe
encompasses the SmaI site in exon 1, giving rise to the same band
pattern on a SmaIlEcoRI blot as the exon 1 probe described by
Merlo et al (1995).
PCR-based methylation assay
Genomic DNA (80 ng) was either digested with 10 U (0.5 U ,tl-')
ofthree methylation-sensitive enzymes (SmaI, HpaII and SacII) or
placed in the appropriate buffer without enzyme (control),
followed by ethanol precipitation. Aliquots of 20 ng of the
digested and non-digested DNA were then amplified by PCR for
28 cycles (primers: 2F and 1108R; see Table 1). The results were
confirmed by two independent DNA digestion and PCR reactions.
As a control for template recovery after ethanol precipitation, a
genomic region not containing any SmaI, HpalI or SacII sites was
amplified.
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Figure 1 The point mutation in GB36. Codon 83 (in exon 2 of CDKN2A) is
mutated in the tumour (CAC to TAC; His to Tyr). Electropherogram windows
obtained with the forward primer (see Table 1) are shown for the tumour and
the corresponding blood. The mutation is indicated by an arrow
RESULTS
In aprevious study, we have deletionmapped9pevaluating 16 loci
including the CDKN2A and CDKN2B genes in a series of 70
primary astrocytic gliomas (Ichimura et al, 1994; Schmidt et al,
1994). Here, we have sequenced the coding region and splice sites
of all retained alleles ofthese two genes in the same tumour series
(see Table 2). Genomic sequences covering all coding sequences
were amplified by PCR using the primers listed in Table 1 and the
products submitted to cycle sequencing.
Among the 48 tumours sequenced, one somatic missense muta-
tion was demonstrated in exon 2 of CDKN2A in a glioblastoma
(GB36) retaining one copy of CDKN2A (Figure 1). At position
287 of the reference sequence (see below), C was replaced by T,
resulting in the substitution of histidine by tyrosine. The mutation
was confirmed by repeating the PCR amplification and
sequencing, and proven to be somatic by comparing it with the
patient's white blood cell DNA. None of the 49 tumours
sequenced for CDKN2B showed any mutations in the entirecoding
region or the splice acceptor and donor sequences.
We found consistent differences in the sequences from the
reported CDKN2A sequence [GenBank, accession number
L27211, ver.8 and intron sequences reported by Kamb et al
(1994a)] in the individual patient's normal white blood cell DNA.
In the non-coding region of exon 1, bases 15, 19 and 22 read G
whereas the reference sequence shows them as A. At position 27
of the reference sequence we found a C/T polymorphism in one
tumour, which was heterozygous at this position. Two of the
patients showed the threonine-alanine polymorphism at position
482 of the reference sequence, which has been described previ-
ously (Cairns et al, 1994; Spruck et al, 1994; Ueki et al, 1994). In
exon 3 of CDKN2A we confirmed the G/C polymorphism located
in the 3' non-coding region at base 540 of the reference sequence,
as described by Ueki et al (1994).
We also found differences from the CDKN2B reference
sequence [GenBank, accession number L36844, ver.2 and intron
sequences reported by Kamb et al (1994a)] in the coding sequence
ofexon 1 confirming thefindings ofGuan et al (1994), who cloned
the CDKN2B cDNA independently. These base changes alter the
expected amino acid sequence from the reference sequence
(between bases 385 and 390 three bases are missing, the amino
acid sequence becoming Ser-Ala-Ala instead of Thr-Pro; and
between bases 418 and 426 a rearrangement of the base sequence
changes His-Ser-Trp to Gln-Leu-Leu). In intron 1 of CDKN2B we
detected a C/A polymorphism 27 nucleotides upstream ofexon 2.
As point mutations ofthe CDKN2A and CDKN2B genes do not
appear to be a major mechanism forthe loss ofa functional protein
we addressed the question of whether lowered or absent transcript
expression could represent an alternative mechanism. Using
RT-PCR we studied 63 tumours (no RNA was available in seven
tumours). A summary of the results is given in Table 2. As
expected, tumours with homozygous deletions of CDKN2A and/or
CDKN2B showed no product after RT-PCR. Only two tumours
(GB151, AA18) showed a detectable signal, which was interpreted
as being derived from the normal cells in the tumour tissue. All
glioblastomas that retained both alleles of CDKN2A and CDKN2B
clearly expressed both genes. Among the glioblastomas that
retained only one copy of these genes, 7/13 (CDKN2A) and 8/11
(CDKN2B) showed no or weak expression (Figure 2). The expres-
sion levels were generally similar for both genes. Among the
anaplastic astrocytomas and astrocytomas, regardless of whether
they retained one or two gene copies, expression ofboth CDKN2A
and CDKN2B showed a heterogeneous pattern. All tumours with
CDK4 amplification that retain one orboth copies ofCDKN2A and
CDKN2B clearly expressed both genes. The mutated CDKN2A
allele in GB36 was also strongly expressed. GB14, which has a
homozygous deletion of CDKN2A but retains one allele of
CDKN2B, did not express CDKN2B.
In order to examine whether decreased expression of the
CDKN2A gene is associated with hypermethylation of its 5' CpG
island (Gonzalez-Zulueta et al, 1995; Herman et al, 1995; Merlo et
al, 1995; Otterson et al, 1995), we assessed the methylation status
of tumours by digesting DNA with methylation-sensitive restric-
tion enzymes. Twenty-one tumours were analysed using
EcoRIISmal digestion and Southern blotting (Figure 3A-C). These
included 15 tumours with hemizygous deletions and six with low
or absent expression of CDKN2A despite the retention of both
alleles. No tumour showed complete methylation ofall SmaI sites.
Three tumours (GB7, A5 and AA13) revealed a pattern consistent
with methylation of one or two SmaI sites in the region (Figure
3A-C and Table 2). However, expression of CDKN2A was seen in
GB7 whereas no expression was detected in A5. Both tumours
showed an identical 0.9-kb band in addition to the expected bands
from unmethylated restriction sites. AA13 showed a 3.3-kb band
in addition to the normal pattern and expressed the transcript. The
identity of the 0.9-kb and 3.3-kb fragments was confirmed by
hybridizing the Southern blots withthe5' and 3' ends ofthe exon 1
probe digested with HpaII (see map in Figure 3A and B; data not
shown). Other tumours, such as GB29 and GB34 showed no
evidence of methylation yet GB29 expressed and GB34 did not
express the CDKN2A transcript (Figure 3C). To confirm these
results and to furthercharacterize tumours with partial methylation
of the 5' CpG island, one SmaI site [SmaI(2)], one Sacll site and
two HpaII sites within exon 1 (Figure 3A) were examined in a
PCR-based methylation assay. No tumour showed clear evidence
ofmethylation of the SmnaI and the HpaII restriction sites (Figure
3D, HpaII data not shown). One tumour (AS) that had been shown
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Table 2 Summary of CDKN2A and CDKN2B allele status, expression and methylation status and CDK4 amplification
Tumoura CDKN2A CDKN2B CDK4
Alleleb Alleleb
number Expressionc Methylationd number Expressionc
GB28
GB21
GB69
GB150
GB2
GB40
GB4
GB17
GB1
GB16
GB45
GB38
GB6
GB22
GB151
GB1 4
GB36
GB24
GB5
GB34
GB23
GB144
GB41
GB8
GB39
GB7
GB30
GB25
GB29
GB26
GB37
GB90
GB142
GB13
GB11
GB154
GB10
GB12
GB15
GB44
GB27
GB105
GB100
AA12
AA49
Ml8
AA2
Ml 3
AA16
AA45
AA17
A4
AA20
AA34
AA52
AA14
Ml 9
AA3
AA50
Al
A10
A7
A22
A5
A21
A6
A2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1, mut
1
1
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
+l-
+l-
+l-
+l-
+
+l
+l
+
+
+
+
+l
+
+l
ND
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
p
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
NA
NA
NA
p
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
p
ND
ND
ND
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
ND
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
AMP*
+l
+l-
+-
+
+
+-
+
+
+l
+l
+l
+l
+l
+l
ND
ND
AMP
AMP
AMP
AMP
AMP
AMP
AMP
AMP
AMP
AMP
AMP
British Journal ofCancer (1997) 75(1), 2-8
All cases studied are listed except three glioblastomas with homozygous deletions for which no RNA was available. aGB, glioblastoma; AA, anaplastic
astrocytoma; A, astrocytoma. bo, homozygous deletion; 1, hemizygous deletion; 2, retention of two alleles; mut, point mutation; ND, not determined.
, Undetectable signal; +/-, weak signal; +, strong signal; ND, not determined. d No methylation; P, partial methylation; NA, not applicable; ND, not
determined. e AMP*, amplification (5 alleles); AMP, amplification (>5 alleles).
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Figure 2 Expression of CDKN2A, CDKN2B and ,B-actin in selected tumours
as determined by RT-PCR. From the left are shown: two examples of the
glioblastomas with homozygous deletions of CDKN2A (GB14, GB150), the
13 glioblastomas with hemizygous deletions (GB7-GB29), 2 of the 14
glioblastomas with retention of both alleles (GB26 which has CDK4
amplification and GB12 without CDK4amplification) and the anaplastic
astrocytoma (AA13) and astrocytoma (A5) that showed partial methylation of
the CDKN2A gene (see also Figure 3). The amount of t-actin PCR product
was confirmed to be in the linear range relative to the quantity of template
under the PCR conditions used (data not shown). Ni, non-neoplastic brain
tissue; N2, total brain RNA (Clontech, Palo Alto, CA, USA)
to have partial methylation of one SmaI site [SmaI(3)] (Figure
3A-C) also revealed methylation ofthe SacII site (Figure 3D).
DISCUSSION
C GB29 GB34 GB7 A5
B T BT BT B T
3.3 kb _
0.9 kb 0
0.65 kb _ _
In this paper we present a thorough analysis of the CDKN2A and
CDKN2B genes in a series of 70 primary astrocytic tumours. By
direct sequencing of the entire coding sequences we found one
somatic mutation in the CDKN2A gene among the 15 tumours
retaining only one allele, and no mutations were found in tumours
retaining both alleles. The single mutation in a glioblastoma
(GB36) results in a substitution of histidine by tyrosine, affecting
the net charge of the translated protein. The substitution changes
the third ankyrin repeat consensus sequence ofp16 (Serrano et al,
1993). An identical mutation has been described in a pancreatic
tumour retaining one allele (Caldas et al, 1994). The protein
resulting from this mutation showed only 8% of wild-type Cdk4
binding activity and could not inhibit Rb phosphorylation in an in
vitro assay (Yang et al, 1995). No somatic mutations were found in
the CDKN2B gene. Point mutations in CDKN2A and CDKN2B
thus appear to be an infrequent event in astrocytic tumours.
Several studies of the CDKN2A and CDKN2B genes in primary
gliomas have been performed using single-strand conformation
polymorphism (SSCP) or sequencing of parts of the coding
sequences (Giani and Finocchiaro, 1994; Ueki et al, 1994, 1996;
Li et al, 1995; Moulton et al, 1995; Sonoda et al, 1995). In total,
four point mutations have been reported, indicating a low
frequency ofpoint mutations in gliomas.
In order to investigate alternative mechanisms that could result
in the absence of a functional protein, we examined the methyla-
tion status of the CDKN2A 5' CpG island and studied the expres-
sion of the transcript. Hypermethylation of the 5' CpG island in
the promoter region and exon 1 of CDKN2A has been reported
to be correlated with transcriptional silencing (Gonzalez-Zulueta
et al, 1995; Herman et al, 1995; Merlo et al, 1995; Otterson et al,
CDKN2A
transcript
_ + _ +
D GB29 GB34 GB7 A5 AA13
N D N D N C N D N D
Sma
Sac 11
Figure 3 Methylation analysis of the 5' CpG island of the CDKN2A gene.
(A) Restriction sites in the region surrounding exon 1 (modified after Merlo et
al, 1995). Positions of the exon 1 probe and primers 2F and 1108R are
indicated. Only restriction sites analysed are shown. Smal and Hpall sites are
numbered. cen, centromere; tel, telomere. (B) Some fragments detectable in
Smal/EcoRl Southern blot analysis using the exon 1 probe. Complete
methylation of the restriction sites analysed should result in a 4.3-kb band
(pattern a). Absence of methylation results in 0.65- and 0.4-kb bands (pattern
b). Methylation of only Smal(3) or both Smal(3) and Smal(4) will result in
patterns c and d respectively. (C) Smal/EcoRl Southern blot analysis (B,
constitutional white blood cell DNA; T, tumour DNA). GB29 and GB34
represent examples of non-methylation showing band pattern b. GB7 and A5
show an additional 0.9-kb band and AA13 an additional 3.3-kb band
consistent with patterns c and d respectively. The presence or absence of the
CDKN2A transcript in the tumours is indicated below the Southern blot (see
also Table 2). The interpretation of the band origin was confirmed by
hybridization with 5' and 3' fragments of the exon 1 probe digested with
Hpall. (D) PCR-based methylation analysis (N, non-digested tumour DNA; D,
digested tumour DNA). No PCR product is detected in any Smal-digested
tumour DNA confirming the lack of methylation at the Smal(2) site. In tumour
A5, a PCR product is detected after Sacil digestion indicating methylation at
the Sacil site, whereas the other tumours did not show clear evidence of
methylation at this site
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1995). Merlo et al (1995) showed that complete methylation of
this region was associated with lack of CDKN2A expression in
NSCLC, small-cell lung cancer and head and neck squamous-cell
carcinoma cell lines. Partial demethylation by 5-deoxyazacytidine
led to expression of the gene. Several primary tumours including
gliomas also showed band patterns consistent with complete or
partial methylation but expression data were not presented (Merlo
et al, 1995). Gonzalez-Zulueta et al (1995) examined the methyla-
tion status of CDKN2A and CDKN2B in primary transitional cell
carcinomas of bladder (TCC) and colon cancer by a PCR-based
methylation analysis and found a correlation between hypermethy-
lation of CDKN2A exon 1 and lack of CDKN2A expression in
TCC. In our series all the 15 tumours retaining one allele of
CDKN2A showed variable expression levels. Two of these
tumours (GB7 and AA13) showed restriction patterns consistent
with partial methylation affecting one or two SmaI sites. However,
both expressed the gene. This could be explained by the presence
of two distinct tumour subpopulations, one of which has some
methylation sites methylated in the CDKN2A 5' CpG region and
does not express the transcript, the other having no methylation
of this region and expressing the gene. These tumours show addi-
tional, strong bands consistent with unmethylated restriction sites
(Figure 3A-C). These bands are unlikely to be derived from
normal cells as the normal cell population in these tumours was
low asjudged by microsatellite and Southern blot analyses as well
as by histopathology of the tissue studied (data not shown). The
presence of subpopulations in these tumour tissues makes correla-
tion between methylation and expression status difficult. All
astrocytomas retained both copies of CDKN2A but three of these
tumours did not appear to express a transcript. In one of these
(A5) partial methylation was seen (of one SacII site and one SmaI
site). In addition to a subpopulation of tumour cells being methy-
lated at these sites, as an explanation for the data one has also
to consider methylation of one or both alleles in this tumour. If
both alleles are methylated at two different sites, this might
explain non-expression in this tumour. All other tumours with
no demonstrable transcript showed no evidence of methylation.
Thus, hypermethylation ofthe 5' CpG island ofthe CDKN2A gene
in astrocytic gliomas is infrequent, and seems to involve only a
few of the potential methylation sites. It does not appear to repre-
sent a common mechanism for the inhibition of CDKN2A gene
expression in these tumours. Many other mechanisms such as
mutations of the promoter region or dysfunction of regulatory
proteins could conceivably be involved in the repression of
expression ofthese genes.
Increased expression of p16 has been demonstrated in Rbl-
negative cells and in cells where the function of RbI has been
impaired by, for example, DNA tumour virus oncoproteins
(Serrano et al, 1993; Li et al, 1994; Parry et al, 1995). A negative
feedback loop between Rbl and p16 has been suggested (Li et al,
1994). The tumours in our series that show strong expression of
CDKN2A could be overexpressing the gene owing to inactivation
ofthe RBI gene by deletion or mutation. This has been confirmed
for some of these tumours in a parallel study in which we exam-
ined the status of the RBI gene in a large number of astrocytic
tumours (Ichimura et al, 1996). Furthermore, CDK4 overexpres-
sion could conceivably result in Rbl hyperphosphorylation,
leading to an increased expression of the CDKN2A transcript. In
agreement with this, all tumours with CDK4 amplification and
overexpression and retaining at least one CDKN2A allele, showed
strong expression of CDKN2A (Table 2).
It has to be noted that an expression study of primary tumour
tissue has obvious limitations due to the presence of normal cells
and the unknown cell cycle states of the tumour and normal cell
populations. Attempts to use the currently available antibodies to
p16 on brain tumour tissue have given unacceptably high back-
ground in our experience. This made evaluation of the findings
extremely difficult. Thus, the cellular location ofp16 in the tumour
tissue is currently difficult to document.
Evidence supporting CDKN2A as a tumour-suppressor gene in
astrocytic tumours is based on the high incidence of homo- and
hemizygous deletions of CDKN2A in glioblastomas. Further
support for CDKN2A as a tumour-suppressor gene in gliomas
comes from a study in which transfection of CDKN2A cDNA into
glioma cell lines lacking CDKN2A resulted in growth inhibition
(Arap et al, 1995). However, as the frequency ofboth mutation and
hypermethylation of the CDKN2A gene is low in gliomas with
hemizygous deletions, the question still remains whether other
gene(s) in the neighbouring region on 9p may contribute to
tumorigenesis of tumours with one intact copy of CDKN2A.
The CDKN2B gene has also been proposed to be a tumour-
suppressor gene. CDKN2B is included in the homo- or hemizy-
gous deletions in all but three tumours in our series (Schmidt et al,
1994) and its protein product p15 is functionally similar to p16
(Serrano et al, 1993; Hannon and Beach, 1994). It can also inhibit
cell proliferation when ectopically expressed in glioma cell lines
(Tenan et al, 1995). However, no mutation was found in the
CDKN2B gene in our present study. Only two missense mutations
have been described in one study ofNSCLC (Okamoto et al, 1995)
and one nonsense mutation in an oesophageal cancer (Suzuki et al,
1995). CDKN2B shows a similar expression level to CDKN2A in
each tumour, suggesting common regulatory motifs. Deletion of
both CDKN2A and CDKN2B may be most advantageous for
progression.
Exons 2 and 3 of the CDKN2A gene have been found to be part
of a novel transcript initiated from an alternative exon I (El )
(Mao et al, 1995; Stone et al, 1995). Recently the mouse homo-
logue of the El transcript was found to encode a novel protein
using an alternative reading frame (Quelle et al, 1995). This
protein, p19ARF, has the ability to induce G,-and G2-phase arrest
when ectopically expressed in rodent fibroblasts. The point muta-
tion detected in GB36 would also change an amino acid in the
corresponding hypothetical human protein derived from the alter-
native reading frame. The human homologue ofp19ARF may repre-
sent yet another tumour-suppressor 'gene' in this region.
In conclusion a comprehensive analysis of the CDKN2A and
CDKN2B genes in primary human astrocytic tumours shows
homozygous deletion to be a frequent mechanism generally
resulting in the loss of both genes. Point mutations of CDKN2A
and CDKN2B are infrequent events. In addition, hypermethylation
of the 5' CpG island of the CDKN2A gene is rare in astrocytic
gliomas.
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